(Q34409105)

2 August 2017

1 reference

title

Therapeutic advances and future prospects in immune-mediated inflammatory myopathies (English)

1 reference

2 August 2017

Marinos C Dalakas

1

1 reference

2 August 2017

publication date

1 November 2008

1 reference

Therapeutic advances in neurological disorders

2 August 2017

published in

1 reference

2 August 2017

volume

1

1 reference

2 August 2017

issue

3

1 reference

2 August 2017

page(s)

157-166

1 reference

Case report: successful treatment of posttransplant lymphoproliferative disorder and quiescence of dermatomyositis with rituximab and sirolimus

2 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002554

Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002554

Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002554

Therapeutic targets in patients with inflammatory myopathies: present approaches and a look to the future

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002554

Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002554

The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002554

Polymyositis and dermatomyositis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002554

Therapeutic approaches in patients with inflammatory myopathies

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002554

Basic principles of immunotherapy for neurologic diseases

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002554

Immunotherapy in autoimmune neuromuscular disorders

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002554

Idiopathic inflammatory myopathies: epidemiology, classification, and diagnostic criteria

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002554

Intravenous immunoglobulin for dysphagia of inclusion body myositis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002554

High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002554

Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002554

Tacrolimus in refractory polymyositis with interstitial lung disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002554

Sporadic inclusion-body myositis and hereditary inclusion-body myopathies: current concepts of diagnosis and pathogenesis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002554

Immunoglobulin therapy in inflammatory myopathies

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002554

Safety and efficacy of strength training in patients with sporadic inclusion body myositis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002554

Treatment of inflammatory myopathies

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002554

Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002554

Immunopathogenesis of inflammatory myopathies

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002554

A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002554

Amyloid filaments in inclusion body myositis. Novel findings provide insight into nature of filaments

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002554

Polymyositis, dermatomyositis and inclusion-body myositis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002554

Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations

6 July 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285608097463

Refractory polymyositis responding to infliximab: extended follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285608097463

Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285608097463

Rapamycin (sirolimus) as a steroid-sparing agent in dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285608097463

Efficacy of tacrolimus in treatment of polymyositis associated with myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285608097463

Steroid-sparing effect of tacrolimus in a patient with juvenile dermatomyositis presenting poor bioavailability of cyclosporine A.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002554

A pilot trial of rituximab in the treatment of patients with dermatomyositis

27 October 2018

1 reference

12 December 2020

T cell receptor profiling in muscle and blood lymphocytes in sporadic inclusion body myositis

1 reference

12 December 2020

Microvascular changes in early and advanced dermatomyositis: a quantitative study

1 reference

12 December 2020

Inclusion body myositis with cricopharyngeus muscle involvement and severe dysphagia

1 reference

12 December 2020

Microvascular deposition of complement membrane attack complex in dermatomyositis

1 reference

12 December 2020

Rituximab in the treatment of dermatomyositis: an open-label pilot study

1 reference

12 December 2020

Treatment of autoimmune inflammatory myopathies

1 reference

12 December 2020

Sirolimus and cyclosporin for renal transplantation

1 reference

12 December 2020

Interplay between inflammation and degeneration: using inclusion body myositis to study "neuroinflammation"

1 reference

12 December 2020

Identifiers

DOI

10.1177/1756285608097463

1 reference

2 August 2017

1 reference

2 August 2017

1 reference